| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | 0.018 | 0.9 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | 0.019 | 0.9 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |